Atherosclerosis, the major cause of ischemic coronary arterydisease and cerebrovascular disease, is a chronic inflammatorydisorder in which immune mechanisms interact with metabolicrisk factors to initiate, propagate, and activate vascular lesions.1Arterial thrombosis, an acute complication that develops onthe surface of a ruptured atheromatous plaque or as a consequenceof endothelial erosion,1 may cause myocardial infarction orischemic stroke. Platelets are key cellular components of arterialocclusive thrombi and may participate in the development andprogression of atheromatous plaques.2 Platelets are also vitalcomponents of hemostasis, the physiologic process that arrestshemorrhage after tissue trauma and vascular . . . [Full Text of this Article]
Pharmacokinetics
Mechanism of Action
Functional Consequences of the Expression and Inhibition of Cyclooxygenase
Clinical Pharmacology of the Inhibition of Platelet Cyclooxygenase
Drug Interactions
Aspirin Resistance
Efficacy and Safety of Low-Dose Aspirin in the Prevention and Treatment of Atherothrombosis in High-Risk Patients
Efficacy and Safety of Low-Dose Aspirin in Low-Risk Subjects
Future Directions
Source Information
From the Department of Pharmacology, University of Rome La Sapienza, Rome (C.P.); the Spanish Center for Pharmacoepidemiologic Research, Madrid (L.A.G.R.); the Department of Medicine, Catholic University School of Medicine, Rome (R.L.); and the Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, United Kingdom (C.B.).
Address reprint requests to Dr. Patrono at University of Rome La Sapienza, Ospedale Sant'Andrea, Via di Grottarossa 1035, 00189 Rome, Italy, or at cpatrono@unich.it.
This article has been cited by other articles:
Leshno, M., Moshkowitz, M., Arber, N.
(2008). Aspirin is Clinically Effective in Chemoprevention of Colorectal Neoplasia: Point. Cancer Epidemiol. Biomarkers Prev.
17: 1558-1561
[Full Text]
Sullivan, J., Amarshi, N.
(2008). Dual antiplatelet therapy with clopidogrel and aspirin. Am J Health Syst Pharm
65: 1134-1143
[Abstract][Full Text]
Hjemdahl, P.
(2008). Should we monitor platelet function during antiplatelet therapy?. Heart
94: 685-687
[Full Text]
Patrono, C., Baigent, C., Hirsh, J., Roth, G.
(2008). Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest
133: 199S-233S
[Abstract][Full Text]
Patrignani, P., Capone, M. L, Tacconelli, S.
(2008). NSAIDs and cardiovascular disease. Heart
94: 395-397
[Full Text]
Bulckaen, H., Prevost, G., Boulanger, E., Robitaille, G., Roquet, V., Gaxatte, C., Garcon, G., Corman, B., Gosset, P., Shirali, P., Creusy, C., Puisieux, F.
(2008). Low-dose aspirin prevents age-related endothelial dysfunction in a mouse model of physiological aging. Am. J. Physiol. Heart Circ. Physiol.
294: H1562-H1570
[Abstract][Full Text]
Comerota, A. J., Thakur, S.
(2008). Antiplatelet Therapy for Vascular Interventions. PERSPECT VASC SURG ENDOVASC THER
20: 28-35
[Abstract]
Landolfi, R., Di Gennaro, L.
(2008). Prevention of thrombosis in polycythemia vera and essential thrombocythemia. haematol
93: 331-335
[Full Text]
Patrono, C., Rocca, B.
(2008). Aspirin: Promise and Resistance in the New Millennium. Arterioscler. Thromb. Vasc. Bio.
28: s25-s32
[Abstract][Full Text]
Wienbergen, H., Senges, J., Gitt, A. K.
(2008). Should We Prescribe Statin and Aspirin for Every Diabetic Patient?: Is it time for a polypill?. Diabetes Care
31: S222-S225
[Full Text]
Krasopoulos, G., Brister, S. J, Beattie, W S., Buchanan, M. R
(2008). Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ
336: 195-198
[Abstract][Full Text]
Davi, G., Patrono, C.
(2007). Platelet Activation and Atherothrombosis. NEJM
357: 2482-2494
[Full Text]
Snoep, J. D., Hovens, M. M. C., Eikenboom, J. C. J., van der Bom, J. G., Huisman, M. V.
(2007). Association of Laboratory-Defined Aspirin Resistance With a Higher Risk of Recurrent Cardiovascular Events: A Systematic Review and Meta-analysis. Arch Intern Med
167: 1593-1599
[Abstract][Full Text]
Nicolucci, A., De Berardis, G., Sacco, M., Tognoni, G.
(2007). AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur Heart J
28: 1925-1927
[Abstract][Full Text]
Capone, M. L., Tacconelli, S., Sciulli, M. G., Anzellotti, P., Di Francesco, L., Merciaro, G., Di Gregorio, P., Patrignani, P.
(2007). Human Pharmacology of Naproxen Sodium. J. Pharmacol. Exp. Ther.
322: 453-460
[Abstract][Full Text]
Siyambalapitiya, S., Bulugahapitiya, U., Sithole, J., Song, S., Fernando, D. J.S., Idris, I.
(2007). Combining Population Health and Baseline Risk Strategy by Determining an Age Cutoff for Initiating Statins in Patients With Diabetes: A population-based study. Diabetes Care
30: 2025-2029
[Abstract][Full Text]
Gelbaya, T.A., Kyrgiou, M., Li, T.C., Stern, C., Nardo, L.G.
(2007). Low-dose aspirin for in vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update
13: 357-364
[Abstract][Full Text]
Nicolucci, A., De Berardis, G., Sacco, M., Tognoni, G.
(2007). Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association: Response to Buse et al.. Diabetes Care
30: e57-e57
[Full Text]
Birnbaum, Y., Lin, Y., Ye, Y., Martinez, J. D., Huang, M.-H., Lui, C. Y., Perez-Polo, J. R, Uretsky, B. F.
(2007). Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin. Am. J. Physiol. Heart Circ. Physiol.
292: H2891-H2897
[Abstract][Full Text]
Chan, A. T., Ogino, S., Fuchs, C. S.
(2007). Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2. NEJM
356: 2131-2142
[Abstract][Full Text]
Faraday, N., Yanek, L. R., Mathias, R., Herrera-Galeano, J. E., Vaidya, D., Moy, T. F., Fallin, M. D., Wilson, A. F., Bray, P. F., Becker, L. C., Becker, D. M.
(2007). Heritability of Platelet Responsiveness to Aspirin in Activation Pathways Directly and Indirectly Related to Cyclooxygenase-1. Circulation
115: 2490-2496
[Abstract][Full Text]
De Caterina, R., Husted, S., Wallentin, L., Agnelli, G., Bachmann, F., Baigent, C., Jespersen, J., Kristensen, S. D., Montalescot, G., Siegbahn, A., Verheugt, F. W.A., Weitz, J.
(2007). Anticoagulants in heart disease: current status and perspectives. Eur Heart J
0: ehl492v1-34
[Full Text]
Chan, A. T., Manson, J. E., Feskanich, D., Stampfer, M. J., Colditz, G. A., Fuchs, C. S.
(2007). Long-term Aspirin Use and Mortality in Women. Arch Intern Med
167: 562-572
[Abstract][Full Text]
Rahme, E., Bardou, M., Dasgupta, K., Toubouti, Y., Ghosn, J., Barkun, A. N.
(2007). Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study. Rheumatology (Oxford)
46: 265-272
[Abstract][Full Text]
Offermanns, S.
(2006). Activation of Platelet Function Through G Protein-Coupled Receptors. Circ. Res.
99: 1293-1304
[Abstract][Full Text]
Madhok, R., Wu, O., McKellar, G., Singh, G.
(2006). Non-steroidal anti-inflammatory drugs--changes in prescribing may be warranted. Rheumatology (Oxford)
45: 1458-1460
[Full Text]
Biondi-Zoccai, G. G.L., Lotrionte, M., Agostoni, P., Abbate, A., Fusaro, M., Burzotta, F., Testa, L., Sheiban, I., Sangiorgi, G.
(2006). A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50 279 patients at risk for coronary artery disease. Eur Heart J
27: 2667-2674
[Abstract][Full Text]
Hallas, J., Dall, M., Andries, A., Andersen, B. S., Aalykke, C., Hansen, J. M., Andersen, M., Lassen, A. T.
(2006). Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ
333: 726-
[Abstract][Full Text]
Ballew, K. A
(2006). Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis. Evid. Based Med.
11: 143-143
[Full Text]
Hennekens, C. H., Sechenova, O., Hollar, D., Serebruany, V. L.
(2006). Dose of Aspirin in the Treatment and Prevention of Cardiovascular Disease: Current and Future Directions.. J CARDIOVASC PHARMACOL THER
11: 170-176
[Abstract]
Kearney, P. M, Baigent, C., Godwin, J., Halls, H., Emberson, J. R, Patrono, C.
(2006). Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.. BMJ
332: 1302-1308
[Abstract][Full Text]
Pfeffer, M. A., Jarcho, J. A.
(2006). The Charisma of Subgroups and the Subgroups of CHARISMA. NEJM
354: 1744-1746
[Full Text]
Chan, A. T., Manson, J. E., Albert, C. M., Chae, C. U., Rexrode, K. M., Curhan, G. C., Rimm, E. B., Willett, W. C., Fuchs, C. S.
(2006). Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events. Circulation
113: 1578-1587
[Abstract][Full Text]
Hankey, G. J., Norman, P. E., Eikelboom, J. W.
(2006). Medical Treatment of Peripheral Arterial Disease. JAMA
295: 547-553
[Abstract][Full Text]